Company intelligence / Profile preview

Shinsei Corporate Investment

Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

Shinsei Corporate Investment (SCI) is an investment firm under SBI Group, specializing in venture, buyout, and impact investments. It has a significant track record with over 2000 due diligence cases, 67 investments, and 20 IPOs, particularly focusing on Health Tech, biotech ventures, and regenerative medicine through co-GP funds.

Industry: Investors

Partnerships

NANO MRNA Co., Ltd.SBI SecuritiesNew Life Science I LLP

Beyond the preview

Go deeper on Shinsei Corporate Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shinsei Corporate Investment.

Explore the full profile